Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience
Identifieur interne : 000014 ( Main/Exploration ); précédent : 000013; suivant : 000015Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience
Auteurs : Calixte Haba Hebane Guehi [France]Source :
Descripteurs français
- mix :
- Wicri :
English descriptors
- mix :
Abstract
The international initiatives for promoting access to antiretroviral therapy (ART) have reduced HIV- related morbidity and mortality. Meanwhile, there are growing cardiovascular risk factors (CVRF) in developing countries, which are witnessing an epidemiological transition. Our objective was to assess the significance of CVRF before and after initiating antiretroviral therapy in HIV-infected people in Africa. Temprano trial aimed to assess the benefits and risks of early antiretroviral therapy and 6-month isoniazid preventive therapy (IPT) after 30-month follow-up. This study concluded that both interventions are effective to reduce severe morbidity, what led WHO, in 2015, to recommend starting ART immediately if CD4 count drop below 500 cells / mm3. In this study, we assessed the prevalence of CVRF and the significance of obesity and overweight at baseline and after 24 months of ART in particular. We then assess the cardiovascular risk score according to the Framingham equation, with and without lipids, at baseline and at the end of follow-up. There were: (i) a positive correlation between the 2 equations (ii) a sharper increase in cardiovascular risks among women and (iii) no difference in the risk increase according to treatment strategies. Finally, in the long-term follow-up of Temprano trial, we are showing the efficacy of IPT on the reduction of mortality, which brings hope in a context where, despite the on-going epidemiological transition, the causes of deaths are still dominated by Tuberculosis in sub- Saharan Africa.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Hal, to step Corpus: 000025
- to stream Hal, to step Curation: 000025
- to stream Hal, to step Checkpoint: 000013
- to stream Main, to step Merge: 000014
- to stream Main, to step Curation: 000014
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience</title><title xml:lang="fr">Facteurs de risque cardiovasculaire chez les patients avant et après initiation des antirétroviraux en Afrique Sub-Saharienne, expérience de l’Essai Temprano ANRS 12 136</title><author><name sortKey="Guehi, Calixte Haba Hebane" sort="Guehi, Calixte Haba Hebane" uniqKey="Guehi C" first="Calixte Haba Hebane" last="Guehi">Calixte Haba Hebane Guehi</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-476572" status="VALID"> <idno type="IdRef">197398162</idno> <idno type="RNSR">201622170H</idno> <orgName> Bordeaux population health </orgName> <orgName type="acronym">BPH</orgName> <desc> <address> <addrLine>Université de Bordeaux - Case 11 - 146 rue Léo Saignat 33076 Bordeaux cedex</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.bordeaux-population-health.center/</ref> </desc> <listRelation> <relation active="#struct-259761" type="direct"></relation> <relation active="#struct-302259" type="direct"></relation> <relation name="U1219" active="#struct-303623" type="direct"></relation> </listRelation> <tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName> <orgName type="acronym">UB</orgName> <desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.u-bordeaux.fr/</ref> </desc> </org></tutelle><tutelle active="#struct-302259" type="direct"><org type="institution" xml:id="struct-302259" status="VALID"> <orgName>Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)</orgName> <desc> <address> <country key="FR"></country> </address> </desc> </org></tutelle><tutelle name="U1219" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc> </org></tutelle></tutelles></hal:affiliation><country>France</country><placeName><settlement type="city">Bordeaux</settlement><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:tel-01498452</idno><idno type="halId">tel-01498452</idno><idno type="halUri">https://tel.archives-ouvertes.fr/tel-01498452</idno><idno type="url">https://tel.archives-ouvertes.fr/tel-01498452</idno><date when="2016-12-22">2016-12-22</date><idno type="wicri:Area/Hal/Corpus">000025</idno><idno type="wicri:Area/Hal/Curation">000025</idno><idno type="wicri:Area/Hal/Checkpoint">000013</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000013</idno><idno type="wicri:Area/Main/Merge">000014</idno><idno type="wicri:Area/Main/Curation">000014</idno><idno type="wicri:Area/Main/Exploration">000014</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience</title><title xml:lang="fr">Facteurs de risque cardiovasculaire chez les patients avant et après initiation des antirétroviraux en Afrique Sub-Saharienne, expérience de l’Essai Temprano ANRS 12 136</title><author><name sortKey="Guehi, Calixte Haba Hebane" sort="Guehi, Calixte Haba Hebane" uniqKey="Guehi C" first="Calixte Haba Hebane" last="Guehi">Calixte Haba Hebane Guehi</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-476572" status="VALID"> <idno type="IdRef">197398162</idno> <idno type="RNSR">201622170H</idno> <orgName> Bordeaux population health </orgName> <orgName type="acronym">BPH</orgName> <desc> <address> <addrLine>Université de Bordeaux - Case 11 - 146 rue Léo Saignat 33076 Bordeaux cedex</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.bordeaux-population-health.center/</ref> </desc> <listRelation> <relation active="#struct-259761" type="direct"></relation> <relation active="#struct-302259" type="direct"></relation> <relation name="U1219" active="#struct-303623" type="direct"></relation> </listRelation> <tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID"> <orgName>Université de Bordeaux</orgName> <orgName type="acronym">UB</orgName> <desc> <address> <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine> <country key="FR"></country> </address> <ref type="url">http://www.u-bordeaux.fr/</ref> </desc> </org></tutelle><tutelle active="#struct-302259" type="direct"><org type="institution" xml:id="struct-302259" status="VALID"> <orgName>Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)</orgName> <desc> <address> <country key="FR"></country> </address> </desc> </org></tutelle><tutelle name="U1219" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno> <orgName>Institut National de la Santé et de la Recherche Médicale</orgName> <orgName type="acronym">INSERM</orgName> <desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine> <country key="FR"></country> </address> <ref type="url">http://www.inserm.fr</ref> </desc> </org></tutelle></tutelles></hal:affiliation><country>France</country><placeName><settlement type="city">Bordeaux</settlement><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author></analytic></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>Africa</term><term>Cardio vascular risks factors</term><term>HIV</term><term>Obesity</term><term>Risk Score</term></keywords><keywords scheme="mix" xml:lang="fr"><term>Afrique</term><term>Facteurs de risques cardio vasculaires</term><term>Obésité</term><term>Scores de risques</term><term>VIH</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Afrique</term><term>Afrique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The international initiatives for promoting access to antiretroviral therapy (ART) have reduced HIV- related morbidity and mortality. Meanwhile, there are growing cardiovascular risk factors (CVRF) in developing countries, which are witnessing an epidemiological transition. Our objective was to assess the significance of CVRF before and after initiating antiretroviral therapy in HIV-infected people in Africa. Temprano trial aimed to assess the benefits and risks of early antiretroviral therapy and 6-month isoniazid preventive therapy (IPT) after 30-month follow-up. This study concluded that both interventions are effective to reduce severe morbidity, what led WHO, in 2015, to recommend starting ART immediately if CD4 count drop below 500 cells / mm3. In this study, we assessed the prevalence of CVRF and the significance of obesity and overweight at baseline and after 24 months of ART in particular. We then assess the cardiovascular risk score according to the Framingham equation, with and without lipids, at baseline and at the end of follow-up. There were: (i) a positive correlation between the 2 equations (ii) a sharper increase in cardiovascular risks among women and (iii) no difference in the risk increase according to treatment strategies. Finally, in the long-term follow-up of Temprano trial, we are showing the efficacy of IPT on the reduction of mortality, which brings hope in a context where, despite the on-going epidemiological transition, the causes of deaths are still dominated by Tuberculosis in sub- Saharan Africa.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement><orgName><li>Université de Bordeaux</li></orgName></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Guehi, Calixte Haba Hebane" sort="Guehi, Calixte Haba Hebane" uniqKey="Guehi C" first="Calixte Haba Hebane" last="Guehi">Calixte Haba Hebane Guehi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000014 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000014 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= BernheimV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Hal:tel-01498452
|texte= Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience
}}
| This area was generated with Dilib version V0.6.33. |  |